Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

For investors looking for yield in the biotech sector, AbbVie is a strong candidate for investment and is in IBD's Dividend Leaders screen.

Top Dividend Stocks: In Biotech Space, AbbVie Entices With 4% Yield

Baxter

Intuitive Surgical

Stryker

Medtronic

Med tech has been on the skids for no fault of its own. It's not the industry's fault that price action was driven to a frothy bubble by COVID-inspired trading outlooks or that the market has normalized.

A Significant Reversal is in Sight for These 5 Med Tech Companies

–  At day 30, approximately 90% of all study patients were satisfied with treatment resulting in a natural look and m ore than 80% of all study patients were satisfied with natural-looking outcomes throughout the 12-month study period for the temporary improvement in the appearance of their moderate to severe upper facial lines1 –  At day 30, more than half of patients experienced a notable difference in self-perceived appearance and psychosocial well-being1 IRVINE, Calif. , Aug. 30, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the Journal of Cosmetic Dermatology published results from a year-long, post-hoc analysis of patient-reported outcomes (PROs) from two Phase 3 clinical studies evaluating the impact of onabotulinumtoxinA (BOTOX® Cosmetic) on upper facial lines (UFLs) in adults new to toxin treatment.

Journal of Cosmetic Dermatology Publishes Data Demonstrating Patient Satisfaction with Natural-Looking Outcomes Following Treatment with OnabotulinumtoxinA (BOTOX® Cosmetic)

ATLANTA--(BUSINESS WIRE)---- $ABBV #7_million_Americans_afflicted--Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug, in Bipolar Disorder Patients.

Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients

CVS Health

Enphase Energy

Intel

NIKE

Paramount Global

Taiwan Semiconductor Manufacturing

Financial opportunities are as abundant as they are volatile. Seizing a selected group of blue-chip stocks to buy could lead to unparalleled investor growth.

Now or Never: 7 Blue-Chip Stocks Offering a Once-in-a-Lifetime Opportunity

AbbVie's (ABBV) regulatory applications filed to the FDA and the EMA seeking approval for Skyrizi for ulcerative colitis are based on data from two phase III studies.

AbbVie (ABBV) Seeks Approval for Skyrizi for Ulcerative Colitis

Costco

Home Depot

Starbucks

The article ranks 5 dividend growth stocks based on their quality, focusing on factors such as balance sheet, management, growth, and stability. The Home Depot is ranked as a "MUST OWN" stock due to its leadership in the home improvement industry and strong dividend growth. AbbVie is ranked as "High-Quality" due to its transition period but still being a solid pharmaceutical company with consistent dividend growth.

Ranking 5 Dividend Growth Stocks From Highest To Lowest Quality

Gilead Sciences

Drugmakers are often great dividend payers, and AbbVie and Gilead are among the best. AbbVie sales are currently dropping, but that shouldn't last for too long.

Nearing Retirement? These Stocks Will Pay You For Life

Eli Lilly

Merck

Amgen

AstraZeneca

Johnson & Johnson

Novartis

Pfizer

Novo Nordisk

Drugs from AbbVie, Bristol and Merck took slots on the list of drugs subject to price cuts. But the pharmaceutical stocks were unmoved.

Blockbusters From AbbVie, Merck, Lilly Highlight List Of 10 Drugs Subject To Price Cuts

Medicare on Tuesday announced the first 10 drugs selected for price negotiations, launching a historic and highly contentious process with big implications for pharmaceutical companies, taxpayers and patients. The selected drugs are the Bristol Myers Squibb Co. BMY, -0.71% blood thinner Eliquis, Boehringer Ingelheim's heart failure drug Jardiance, Johnson and Johnson JNJ, -1.18% blood thinner Xarelto, Merck & Co. Inc. MRK, -1.16% diabetes drug Januvia, AstraZeneca AZN, +0.57% heart failure drug Farxiga, Novartis AG NVS, +0.55% heart failure drug Entresto, Amgen Inc. AMGN, +0.07% rheumatoid arthritis drug Enbrel, AbbVie Inc. ABBV, +0.50% blood cancer drug Imbruvica, Johnson and Johnson psoriasis treatment Stelara, and Novo Nordisk NVO, +0.57% insulin Fiasp.

Merck, Amgen, AbbVie products among first 10 drugs selected for Medicare price negotiations

Apple

Microsoft

Netflix

NVIDIA

Oracle

The NASDAQ index, which lost one-third of its value last year, has rebounded with vigor in the first half of 2023. It climbed a staggering 32% during the period, channeling the spirit of 1983 when the tech-heavy index shot up 37% in value.

7 Stocks to Buy for the Rest of 2023

Cintas Corp

Paycom Software

ResMed

Tractor Supply

Ulta Beauty

With summer coming to an end, investors may want to target certain compelling stocks to buy now. Basically, the theory is the reverse of the adage, sell in May and go away.

Late-Summer Steals: 7 Stocks to Buy Before Fall

Submissions are supported by two Phase 3 clinical trials demonstrating risankizumab achieved the primary endpoint of clinical remission (per Adapted Mayo Score) and key secondary endpoints as an induction and maintenance treatment1,2 Safety results were generally consistent with the known safety profile of risankizumab, with no new safety risks observed1,2  Risankizumab is an IL-23 inhibitor being evaluated as a treatment for adults with moderately to severely active ulcerative colitis and is currently approved by FDA and EMA in Crohn's disease, psoriatic arthritis and psoriasis1 NORTH CHICAGO, Ill. , Aug. 28, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for risankizumab (SKYRIZI®, 1200 mg intravenous [IV] [induction dose] and 180 mg and 360 mg subcutaneous [SC] [maintenance dose]) for the treatment of adult patients with moderately to severely active ulcerative colitis.

AbbVie Submits Regulatory Applications to FDA and EMA for Risankizumab (SKYRIZI®) in Ulcerative Colitis

Broadcom

In the fast-paced arena of stock trading, a glittering prize awaits those with the acumen to spot it: affordable growth stocks.

2 Stocks With Growth Potential

AbbVie's (ABBV) newer products, Skyrizi and Rinvoq, are performing extremely well and have the potential to make up for lost Humira revenues.

Can AbbVie (ABBV) Protect Revenues After Humira Patent Loss?

AbbVie investors have good reason to be concerned about the company's future return potential. Sales are expected to fall markedly this year due to the patent expiration of Humira in domestic markets. And judging by its dividend yields (3.94% currently), the stock's valuation is no longer cheap.

AbbVie: Still A Buy According To Buffett's 10xEBT Rule

Kinder Morgan

Morgan Stanley

Philip Morris

Southern Company

If you have the temptation to speculate, but are hesitant to go full bore into the madness of memes, oversold high-yield stocks to buy offer plenty of punch. Specifically, I'm focusing on well-established enterprises that just haven't aligned with market sentiment.

7 Very Oversold High-Yield Stocks to Buy Right Now

Automatic Data Processing

Chevron

Lockheed Martin

Lowe's

PepsiCo

UnitedHealth Group

When it comes to investing in dividend stocks, some investors focus mainly on yield. This can sometimes lead to investing too heavily in stocks that, while offering a high yield, could end up becoming dividend traps, whether from cutting/suspending their dividends, and/or from shares declining in value, outweighing the large payouts.

7 Top Dividend Stocks for Income and Stability

Large-cap pharmaceuticals have enjoyed buying pressure over the last month, delivering outsized gains to investors. And these three stocks have helped lead the charge.

These 3 Large-Cap Pharma Stocks Have Been Red-Hot

Visa

A trillion-dollar valuation by a single company was once unthinkable even just a few years ago. After all, the S&P 500 was created in 1957 when the total market capitalization of the index was $172 billion.

Trillion-Dollar Trio: These 3 Super Growth Stocks Will Dominate the Market by 2035

Following the approval, AbbVie's (ABBV) Aquipta is the first and the only oral CGRP receptor antagonist approved in the EU to prevent episodic and chronic migraines.

AbbVie (ABBV) Gets EU Approval for Migraine Prevention Drug

AbbVie is managing its much-anticipated loss of U.S. patent exclusivity for Humira as well as could be expected. The rest of the company's business is strong, and it looks in no danger of decreasing or suspending its dividend.

1 High-Yield Dividend Stock That Looks Like a Screaming Buy

AQUIPTA ® (atogepant) is the first and only once-daily oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) in the European Union (EU) approved for the prophylaxis of migraine in adults who have four or more migraine days per month Approval is based on two pivotal Phase 3 studies that demonstrated statistically significant reduction in mean monthly migraine days with AQUIPTA compared to placebo in adult patients with both chronic and episodic migraine The approval expands AbbVie's portfolio of therapies for adult patients in the EU across migraine frequencies , including episodic and chronic migraine NORTH CHICAGO, Ill. , Aug. 17, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission has approved AQUIPTA ®  (atogepant) for the prophylaxis of migraine in adults who have four or more migraine days per month.

AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Preventive Treatment of Migraine in Adults

News for AbbVie Stock (ABBV)